SCHEMBL4117255

SCHEMBL4117255

Cc1ccc(C)c(-c2nc3ccccc3[nH]2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.71
RAB9A P51151 12/20 0.71
ALDH1A1 P00352 10/20 0.71
SMN1; SMN2 Q16637 10/20 0.71
HPGD P15428 6/20 0.71
NPSR1 Q6W5P4 3/20 0.71
HTT P42858 1/20 0.71
KDM4E B2RXH2 8/20 0.67
MAPT P10636 5/20 0.67
HSD17B10 Q99714 4/20 0.67
GAA P10253 4/20 0.67
RECQL P46063 1/20 0.67
THRB P10828 1/20 0.56
PKM P14618 4/20 0.56
TP53 P04637 2/20 0.56
ABCB11 O95342 1/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8957841 0.87 RAB9A (0.71) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL21976303 0.87 MAPT (0.80) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL3834420 0.84 ALDH1A1 (0.68) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL31429745 0.84 F2 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL29056621 0.84 NPC1 (0.67) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL12071677 0.84 ALDH1A1 (0.69) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL16142437 0.84 F2 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL30641666 0.84 AMY1A (0.62) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL29269110 0.84 AMY1A (0.62) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL29595013 0.84 F2 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117778-A9 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS INC (US) 2009-05-22 WO disclosed
EP-1986747-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS Kalypsys, Inc. (US) 2008-11-05 EP disclosed
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2008-06-12 US disclosed
WO-2007117778-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS NOS2, NOS1, NQO2 NPC1 1303/4885RAB9A 1758/4885ALDH1A1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.